Information Provided By:
Fly News Breaks for October 24, 2018
NEO
Oct 24, 2018 | 06:18 EDT
First Analysis analyst Joseph Munda upgraded NeoGenomics to Strong Buy and raised his price target for the shares to $18 from $16. The analyst views the company's acquisition of clinical oncology testing leader Genoptix as a "major positive." The combined company should benefit from greater geographical coverage, a broader test menu, enhanced service capabilities, and deeper access to oncologists, Munda tells investors in a research note.
News For NEO From the Last 2 Days
There are no results for your query NEO